Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Madrigal Pharma

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. …

Benzinga · Jun 27, 2022

Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch

Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) secured a $250 million term loan facility from Hercules Capital Inc (NYSE:HTGC), providing additional funding to support the expanded clinical program and ramp-up for a potential US launch of resmetirom. The company drew $50 million from the facility at closing and can draw a further $200 million under the agreement. Related…

Benzinga · May 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

424,263 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play